SCHEMBL5541961

SCHEMBL5541961

O=COCCc1coc2cc(F)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.44
CYP11B2 P19099 3/20 0.44
CYP19A1 P11511 2/20 0.44
CYP17A1 P05093 1/20 0.44
PTPN1 P18031 1/20 0.38
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
HTR6 P50406 1/20 0.34
HTR1A P08908 3/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543456 0.89 CYP11B1 (0.41) CYP11B1CYP11B2CYP19A1CYP17A1PTPN1
SCHEMBL5540067 0.89 PTPN1 (0.48) CYP11B1CYP11B2CYP19A1CYP17A1PTPN1
SCHEMBL5545744 0.83 PTPN1 (0.38) PTPN1SMN1; SMN2MAPTALOX15MAOA
SCHEMBL27962001 0.81 HTR6 (0.40) PTPN1HTR6HTR1AMAOAMAOB
SCHEMBL5540063 0.80 CYP11B1 (0.44) CYP11B1CYP11B2CYP19A1CYP17A1PTPN1
SCHEMBL27962075 0.79 KDM1A (0.37) CYP11B1CYP11B2CYP19A1CYP17A1TSHR
SCHEMBL27822551 0.79 MAOB (0.46) CYP11B1CYP11B2CYP19A1CYP17A1PTPN1
SCHEMBL5544391 0.79 PTPN1 (0.44) PTPN1HTR6HTR1AKDM4EDRD3
SCHEMBL27962074 0.76 SMN1; SMN2 (0.34) SMN1; SMN2MAPTHTR6KDM4ENPC1
SCHEMBL5542281 0.74 PTPN1 (0.33) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP11B1 514/4885CYP11B2 373/4885CYP19A1 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.